Activartis: substantial amendment to trial

The ethics committee of Land Oberösterreich as well as the Austrian drug agency AGES PharmMed approved a substantial amendment to our GBM-Vax trial.

This is intended to maintain the quality of final results and deliver first evidence for efficacy of Activartis’ Cancer Immune Therapeutic. Up to 20 patients aged 18-70 years may be recruited for GBM-Vax. In addition, patients older 70 years may from now on also be recruited for the study. However, similarly to paediatric patients 3-18 years, elderly patients will not be randomised and will not be analysed together with patients 18-70 years.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)